[
    {
        "Gene name":"AKT2",
        "Genomic Position":"19:40736224-40791302(-) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AKT2_Amplification",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus,Vandetanib",
        "Description":"Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET, as well as an AKT2 gene amplification. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET\/CT showed systemic response as well.",
        "rs value":null,
        "pmid":"PubMed:25982012",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S310Y",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31543779",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RB1",
        "Genomic Position":"13:48877911-49056122(+) | 13q14.2",
        "CDS Mutation":null,
        "AA Mutation":"RB1_Mutation",
        "Disease":"Lung Small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy",
        "Description":"Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease. Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds ratio 5.58 compared to WT, p=.038). Kaplan-Meier survival analysis revealed patients with RB1 mutations exhibited better overall survival (p = .04, 11.7 versus 9.1 months, CI = 1.1-28.2).",
        "rs value":null,
        "pmid":"PubMed:26802149",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SMARCA4",
        "Genomic Position":"19:11071677-11172958(+) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"SMARCA4_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vinorelbine,Cisplatin",
        "Description":"SMARCA4 expression was determined with gene expression microarray in 133 patients. Improved five-year disease-specific survival (DSS) was noted only in patients with low SMARCA4 expression when treated with adjuvant cisplatin\/vinorelbine (n=36) (HR=0.1, 95% CI: 0.0-0.5, P=0.002 [low]; HR 1.0, 95% CI: 0.5-2.3, P=0.92 [high]) compared to patients in the observation arm (N=30).",
        "rs value":null,
        "pmid":"PubMed:26671993",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_Mutation",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pembrolizumab,Atezolizumab,Nivolumab",
        "Description":"In a retrospective analysis in two separate datasets (Stand Up To Cancer 2 Cohort and Checkmate-057), patients with concomitant KRAS and STK11 mutations had significantly worse response rates, PFS and OS compares to KRAS only and KRAS-TP53 Mutant Patients. This work identifies STK11\/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.",
        "rs value":null,
        "pmid":"PubMed:29773717",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + PBF-1129",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05234307",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Sarilumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05704634",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05469178",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bemcentinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03184571",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sirpiglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04471415",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed + Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04265534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04173507",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"STK11",
        "Genomic Position":"19:1205740-1228428(+) | 19p13.3",
        "CDS Mutation":null,
        "AA Mutation":"STK11_S69*",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19589612",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2389T>G",
        "AA Mutation":"p.C797G",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28104619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26400668",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23912954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23180674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22215752",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21921847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21062933",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19381876",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2375T>G",
        "AA Mutation":"p.L792R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24369725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2374C>T",
        "AA Mutation":"p.L792F",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2374C>T",
        "AA Mutation":"p.L792F",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31632838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2153T>A",
        "AA Mutation":"p.L718Q",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27257132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26862733",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21430269",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18676761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27304188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2390G>C",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23886554",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17192902",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2153T>A",
        "AA Mutation":"p.L718Q",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32777674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22052230",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21430269",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29110836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20682976",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31542322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2239",
        "AA Mutation":"p.L747P",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29673089",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24034463",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16983123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2153T>A",
        "AA Mutation":"p.L718Q",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31632838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24752053",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21315472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18379370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25982275",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17020982",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2281G>T",
        "AA Mutation":"p.D761Y",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17085664",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29807405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2389T>A",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27257132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2386G>A",
        "AA Mutation":"p.G796S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23079729",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27553514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31632838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28978102",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21921847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2152C>G",
        "AA Mutation":"p.L718V",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29110836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24781527",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28104619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2386G>A",
        "AA Mutation":"p.G796S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17085664",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20146086",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18992959",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28572531",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20871262",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C797G",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29807405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26612314",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25939061",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25120654",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25130612",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2389T>G",
        "AA Mutation":"p.C797G",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31542322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2390G>C",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19238633",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31761448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27304188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26746366",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24029120",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23037472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17335935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:20686428",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2374C>T",
        "AA Mutation":"p.L792F",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17085664",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21995391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16014893",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:16198442",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23466741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31561203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19596957",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18509184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29106415",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24468202",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17973572",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17332333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2156G>C",
        "AA Mutation":"p.G719A",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2375T>A",
        "AA Mutation":"p.L792H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2375T>A",
        "AA Mutation":"p.L792H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22993320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22228822",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21030498",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:18271876",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L718Q",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29807405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23407566",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31157314",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28274743",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22108465",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31543779",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31542322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19181917",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24457237",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31561203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2386G>C",
        "AA Mutation":"p.G796R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19155283",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24942894",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24636847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22815900",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19692934",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21573178",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2386G>C",
        "AA Mutation":"p.G796R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:19272767",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31761448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2375T>A",
        "AA Mutation":"p.L792H",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31632838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21623281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24813888",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2375T>C",
        "AA Mutation":"p.L792P",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23139670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17180521",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:33260286",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29120087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.M766Q",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31254668",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2389T>A",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28625641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27895763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675505",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22108465",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:15728811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2374C>G",
        "AA Mutation":"p.L792V",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17699786",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24729716",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28031840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G796D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28572531",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26424310",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24555578",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22895145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2389T>A",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31632838",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23579627",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22071596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:17145836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22773810",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24035188",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21135146",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23542356",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24105277",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25939061",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27528220",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:21921847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28104619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2369C>T",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30711944",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31761448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31561203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"XL647",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22722787",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.2390G>C",
        "AA Mutation":"p.C797S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"HM61713",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26749488",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T790M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Icotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31558230",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"POLD1",
        "Genomic Position":"19:50887596-50921271(+) | 19q13.3",
        "CDS Mutation":null,
        "AA Mutation":"POLD1_C284Y",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":"In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in any patients who did not experience a durable clinical benefit.",
        "rs value":null,
        "pmid":"PubMed:25765070",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"POLD1",
        "Genomic Position":"19:50887596-50921271(+) | 19q13.3",
        "CDS Mutation":null,
        "AA Mutation":"POLD1_E374K",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":"In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in patients who did not experience a durable clinical benefit.",
        "rs value":null,
        "pmid":"PubMed:25765070",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERCC1",
        "Genomic Position":"19:45916692-45926824(-) | 19q13.32",
        "CDS Mutation":null,
        "AA Mutation":"ERCC1_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine,Carboplatin",
        "Description":"As part of a randomized phase III trial (USO-03012) in advanced NSCLC of gemcitabine vs. combination gemcitabine and carboplatin, protein expression levels for RRM1 (n=69) and ERCC1 (n=65) were evaluated using fluorescence-based IHC. RRM1 levels were significantly inversely correlated with response (r = \ufffd\ufffd\ufffd0.41; P = .001, n=58), as were ERCC1 levels (r = \ufffd\ufffd\ufffd0.39; P = .003, n=55). RRM1 and ERCC1 levels were correlated with each other (r = 0.36; P = .003, n=65). There was no significant interaction with treatment arm (P = .64 for RRM1; P = .79 for ERCC1). The authors conclude that RRM1 and ERCC1 expression levels are predictive of response to gemcitabine, and gemcitabine and ",
        "rs value":null,
        "pmid":"PubMed:19884554",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"GNAS",
        "Genomic Position":"20:57427769-57486247(+) | 20q13.32",
        "CDS Mutation":null,
        "AA Mutation":"GNAS_c.393T>C",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib,Erlotinib",
        "Description":"The disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype (TT or CT) (46.2% vs 73.8%, P=0.039). Univariate analysis identified gender, smoking history, histology and GNAS1 T393C polymorphism as predictive marker of PFS (P=0.04, P<0.001, P<0.001 and P=0.005). Multivariate analysis of factors, including smoking history, performance status score, histology, GNAS1 T393C polymorphism demonstrated that GNAS1 T393C polymorphism was correlated independently with PFS (P=0.007). The data suggests the role of GNAS1 T393C CC genotype as a poor predictive marker both of DCR and PFS in advanced NSCLC patients treated with tyrosine kinase inhibitor.",
        "rs value":null,
        "pmid":"PubMed:24758907",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BIRC5",
        "Genomic Position":"17:76210267-76221717(+) | 17q25.3",
        "CDS Mutation":null,
        "AA Mutation":"BIRC5_NUCLEAR_EXPRESSION",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Taxane Compound,Platinum Compound",
        "Description":"Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective analysis of 48 patients with non-small cell lung cancer.",
        "rs value":null,
        "pmid":"PubMed:24961465",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BCL2L11",
        "Genomic Position":"2:111878506-111926024(+) | 2q13",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L11_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gefitinib + Vorinostat",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02151721",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L11",
        "Genomic Position":"2:111878506-111926024(+) | 2q13",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L11_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + EGFR-TKI",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L11",
        "Genomic Position":"2:111878506-111926024(+) | 2q13",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L11_Deletion_Polymorphism",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor",
        "Description":"The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779). Introduction of this polymorphism in a previously EGFR-inhibitor sensitive cell line led to TKI-resistance. In 141 NSCLC patients with EGFR mutations, the presence of the polymorphism (N=26) was predictive of a significantly shorter PFS under treatment with EGFR-TKI (6.6 months vs. 11.9 months, p = 0.0027). Patients received either gefitinib only (N=136) or erlotinib only (N=5).",
        "rs value":null,
        "pmid":"PubMed:22426421",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AURKA",
        "Genomic Position":"20:54944445-54967351(-) | 20q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AURKA_Overexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Cisplatin",
        "Description":"High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisplatin-based chemotherapy. In-vitro data confirmed these results and overexpression or knockdown of AURKA decreased or increased in-vitro sensitivity to cisplatin.",
        "rs value":null,
        "pmid":"PubMed:25082261",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_Amplification",
        "Disease":"Lung Squamous Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":"Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). In the subgroup of FGFR1-amplified squamous NSCLC (as classified by FISH), 36 patients were treated at doses >100mg continuously and disease control was achieved in 50% of patients (4 PR and 14 SD) with 6 patients receiving treatment after 16 weeks. Of the 27 patients who had evaluable pre- and post- treatment target lesion assessments, 11 had reduced tumor burden.",
        "rs value":null,
        "pmid":"PubMed:27870574",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pazopanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00367679",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_Amplification",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":"Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partial response, 38.5% exhibited stable disease. Median PFS was 2.9 months, median OS was 5 months, this trend was worse with increases in FGFR1 amplification above average.",
        "rs value":null,
        "pmid":"PubMed:27315356",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"(FGFR1_unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified)_and_CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05004974",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02668393",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lucitanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02109016",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Regorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01187615",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02856425",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pazopanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02193152",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02117167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547 + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01824901",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Methotrexate + Regorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03520842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05210946",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01948141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01861197",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01676714",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02231164",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pazopanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01208064",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00979134",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Infigratinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01004224",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01795768",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00979134",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02965378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02154490",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02699606",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05287386",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05253807",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rogaratinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03762122",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":null,
        "AA Mutation":"FGFR1_Amplification",
        "Disease":"Adenosquamous Lung Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pazopanib",
        "Description":"Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC.  Patient was treated with 400 mg pazopanib twice a day.  CT taken four and eight weeks after start of pazopanib showed tumor regression and cavitation.   Due to side effects, patient stopped taking pazopanib after 6 months.  No clinical or radiologic signs of tumor progression were present at that time.",
        "rs value":null,
        "pmid":"PubMed:24302556",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_Overexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pemetrexed",
        "Description":"mRNA expression of thymidylate synthase (TYMS) in 62 NSCLC patients correlated with response rate to pemetrexed mono- or combination therapy. Response rate with low TYMS expression was 0.29 compared with 0.03 in patients with overexpression (P = 0.025). Patients with low expression exhibited a benefit in time to progression (average TTP = 56 vs. 23 months, P = 0.001) and in overall survival (average OS = 60 vs. 25 months, P = 0.002).",
        "rs value":null,
        "pmid":"PubMed:26502926",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_Amplification",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pemetrexed",
        "Description":"TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines.",
        "rs value":null,
        "pmid":"PubMed:23645741",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemetrexed",
        "Description":"49 tumor specimens from 268 NSCLC patients treated with pemetrexed were evaluated for expression of TYMS and DHFR by IHC and compared to treatment outcomes. Patients with low TS (\ufffd\ufffd\ufffd150) expression had a longer median progression-free survival (PFS) than those with high TS (>150) expression (4.8 vs. 3.4 months; p=",
        "rs value":null,
        "pmid":"PubMed:21367480",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TYMS",
        "Genomic Position":"18:657604-673578(+) | 18p11.32",
        "CDS Mutation":null,
        "AA Mutation":"TYMS_Overexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Pemetrexed",
        "Description":"mRNA levels of TYMS, DHFR and GARFT were assessed (rt-PCR) in 50 patient samples of NSCLC. TYMS mRNA levels were lower in responders compared to non-responders to pemetrexed (1.671 \ufffd\ufffd 0.844 versus 5.978 \ufffd\ufffd 1.895, p=",
        "rs value":null,
        "pmid":"PubMed:23060591",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ETS2",
        "Genomic Position":"21:40177231-40196879(+) | 21q22.2",
        "CDS Mutation":null,
        "AA Mutation":"ETS2_RS461155",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel,Cisplatin",
        "Description":"Eighty SNPs in miRNA binding sites of cancer related genes selected from 18,500 miRNA:target bindings in crosslinking, ligation, and sequencing of hybrids (CLASH) data were investigated in 379 advanced NSCLC patients using a sequenom mass spectrometry-based genotype assay. 16 SNPs were significantly associated with the clinical outcomes after chemotherapy with paclitaxel-cisplatin: ETS2 SNP: OR = 1.34, 95% CI = 1.00\ufffd\ufffd\ufffd1.81, P = 0.05; aHR = 0.80, 95% CI = 0.69\ufffd\ufffd\ufffd0.94, P = 0.006, under additive model. ETS2 rs461155A>G was significantly associated with decreased ETS2 mRNA expression in both tumor and paired normal lung tissues (Ptrend = 4 \ufffd\ufffd 10-7, and 3 \ufffd\ufffd ",
        "rs value":null,
        "pmid":"PubMed:26893365",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"DDR2",
        "Genomic Position":"1:162602255-162757190(+) | 1q23.3",
        "CDS Mutation":null,
        "AA Mutation":"DDR2_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01491633",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"DDR2",
        "Genomic Position":"1:162602255-162757190(+) | 1q23.3",
        "CDS Mutation":null,
        "AA Mutation":"DDR2_S768R",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib,Dasatinib",
        "Description":"In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.",
        "rs value":null,
        "pmid":"PubMed:22328973",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib,Erlotinib",
        "Description":"In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. PIK3CA mutations (n=6) were associated with no difference in objective response to drug treatment (16.6% vs. 35.2%, p=0.61), shorter overall survival (9.9 vs. 30.2 months, p<0.001), and shorter median time to progression (2.3 vs. 6.0 months, p=0.01) when compared to wild-type PIK3CA. Through multivariate analyses, it was shown that PIK3CA mutations are significant predictors of worse overall survival (HR: 5.81, 95% CI: 2.43-13.91, p=0.0001) and shorter time to progression (HR: 2.71 95% CI: 1.23-4.79, p=0.03).",
        "rs value":null,
        "pmid":"PubMed:21258250",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Carboplatin + Paclitaxel + Pictilisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01493843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib + Dacomitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01121575",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02276027",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Pictilisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01493843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_E545K",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib,Erlotinib",
        "Description":"48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 2 out of the 39 patients had the E545K PIK3CA mutation in the absence of EGFR T790M, indicating that E545K may be an alternative mutation contributing to resistance.",
        "rs value":null,
        "pmid":"PubMed:27304188",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ABCB1",
        "Genomic Position":"7:87133175-87342564(-) | 7q21.12",
        "CDS Mutation":null,
        "AA Mutation":"ABCB1_I1145I",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Carboplatin",
        "Description":"The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC).  103 Chinese patients with NSCLC were evaluated in this study. However, there was not a significant correlation between the mutation and overall survival.",
        "rs value":null,
        "pmid":"PubMed:22296372",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30683630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174C",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174C",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31374369",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27130468",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3367G>A",
        "AA Mutation":"p.G1123S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26134233",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202del",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.I1171S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3538G>C",
        "AA Mutation":"p.V1180L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25228534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174V",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V1180L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.I1171T",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3607G>A",
        "AA Mutation":"p.D1203N",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28434515",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>C",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31374369",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174L",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Ceritinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3512T>A",
        "AA Mutation":"p.I1171N",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25393796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3512T>G",
        "AA Mutation":"p.I1171S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25393796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.I1171S",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26464158",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3512T>A",
        "AA Mutation":"p.I1171N",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25393798",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T1151R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174L",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C1156Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S1206F",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.T1151M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3512T>C",
        "AA Mutation":"p.I1171T",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25393798",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S1206Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3467G>A",
        "AA Mutation":"p.C1156Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27045755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23434628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S1206Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174C",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3383G>C",
        "AA Mutation":"p.G1128A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30089600",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3586C>A",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23344087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3617C>A",
        "AA Mutation":"p.S1206Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22277784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S1206C",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24675041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.I1171T",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F1174V",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3467G>A",
        "AA Mutation":"p.C1156Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23434628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23344087",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31668326",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22277784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.S1206Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3586C>A",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:23434628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3586C>A",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22277784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31668326",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3520T>G",
        "AA Mutation":"p.F1174V",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24736079",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1203N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Brigatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27045755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1152R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24736079",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C1156F",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31712133",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31749991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3451",
        "AA Mutation":"p.T1151dup",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22277784",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.E1210K",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27432227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1204V",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29650534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31749991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3512T>G",
        "AA Mutation":"p.I1171S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31943796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3604G>A",
        "AA Mutation":"p.G1202R",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31749991",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.3806G>C",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31943796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.I1171N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31616196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1196M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29650534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L1198F",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29650534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1269A",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Lorlatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29650534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NFE2L2",
        "Genomic Position":"2:178095033-178129859(-) | 2q31.2",
        "CDS Mutation":null,
        "AA Mutation":"NFE2L2_Mutation",
        "Disease":"Lung Squamous Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sapanisertib",
        "Description":"In an NCI-CTEP phase 2 trial, patients with squamous cell lung carcinoma with NFE2L2 mutations were treated with TORC1\/2 inhibitor TAK-228. The response rate was 29% (2\/7\ufffd\ufffd\ufffdand disease control rate was 100%. NFE2L2 mutations included Exon 2 deletion, F37V, D29H, W24C, E79K, G31R, R34G, R34Q, W24R, D77H, and",
        "rs value":null,
        "pmid":"ASCO:174406",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NFE2L2",
        "Genomic Position":"2:178095033-178129859(-) | 2q31.2",
        "CDS Mutation":null,
        "AA Mutation":"NFE2L2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed + Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04265534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NFE2L2",
        "Genomic Position":"2:178095033-178129859(-) | 2q31.2",
        "CDS Mutation":null,
        "AA Mutation":"NFE2L2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sirpiglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04471415",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDCD4",
        "Genomic Position":"10:112631565-112659764(+) | 10q25.2",
        "CDS Mutation":null,
        "AA Mutation":"PDCD4_EXPRESSION",
        "Disease":"Lung Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel",
        "Description":"PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker.",
        "rs value":null,
        "pmid":"PubMed:25928036",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERCC2",
        "Genomic Position":"19:45853095-45873876(-) | 19q13.32",
        "CDS Mutation":null,
        "AA Mutation":"ERCC2_K751Q",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin,Paclitaxel",
        "Description":"The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC). The researchers utilized data from three previous clinical trials in Japan and the United States with a total of 526 NSCLC patients.",
        "rs value":null,
        "pmid":"PubMed:19470925",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Cisplatin + Olaparib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04318938",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04533321",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Wildtype",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adjuvant Chemotherapy",
        "Description":"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA, 1209 patients, median follow-up 5.5 years) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with wild-type TP53 had better outcomes with ACT than OBS (HROS=0.77 [0.62-0.95], p=0.02; HRDFS=0.75 [0.62-0.92], p=0.005).",
        "rs value":null,
        "pmid":"PubMed:26899019",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | bronchioloalveolar adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004225",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00378404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01574729",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04022876",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00617409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Tretinoin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00617409",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04459663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + Erfonrilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05420220",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel or Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04194203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03896074",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT04426825",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03666728",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04563338",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02366143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Axitinib + SEA-TGT + Sasanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04585815",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02998528",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03215706",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Evolocumab + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05144529",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Ipilimumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03430063",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02477826",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Ipilimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03515629",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_or_KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03225664",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02477826",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02659059",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02659059",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04013542",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03469960",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab + Stereotactic radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03223155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03302234",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03351361",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Ipilimumab + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03515629",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01642004",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":"Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC3\ufffd\ufffd\ufffd50%, TC2\ufffd\ufffd\ufffd5% and <50%, TC1\ufffd\ufffd\ufffd1% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3\ufffd\ufffd\ufffd10%, IC2\ufffd\ufffd\ufffd5% and <10%, IC1\ufffd\ufffd\ufffd1% and <5%, and IC0<1%). Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 0\ufffd\ufffd49 [0\ufffd\ufffd22-1\ufffd\ufffd07; p=0\ufffd\ufffd068], TC2\/3 or IC2\/3 HR 0\ufffd\ufffd54 [0\ufffd\ufffd33-0\ufffd\ufffd89; p=0\ufffd\ufffd014], TC1\/2\/3 or IC1\/2\/3 HR 0\ufffd\ufffd59 [0\ufffd\ufffd40-0\ufffd\ufffd85; p=0\ufffd\ufffd005], TC0 and IC0 HR 1\ufffd",
        "rs value":null,
        "pmid":"PubMed:26970723",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01673867",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD7789",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04931654",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel or Nab-paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02775435",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab,Atezolizumab,Avelumab,Nivolumab",
        "Description":"Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1\/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining \ufffd\ufffd\ufffd1%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-",
        "rs value":null,
        "pmid":"PubMed:26918451",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":"This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK. Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group.",
        "rs value":null,
        "pmid":"PubMed:27718847",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02998528",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":"PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab.",
        "rs value":null,
        "pmid":"PubMed:25891174",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab + Cryoablation",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04201990",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | large cell neuroendocrine carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Durvalumab + Etoposide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05262985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02366143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03088540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Interleukin-2 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05493566",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab,Atezolizumab,Avelumab,Pembrolizumab,Durvalumab",
        "Description":"In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89).",
        "rs value":null,
        "pmid":"PubMed:28472902",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Durvalumab + Paclitaxel + Papaverine + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05136846",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02007070",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Durvalumab + Oral Restorative Microbiota Therapy + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04105270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pegilodecakin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03382899",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02142738",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02486718",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02367781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01905657",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02220894",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Penpulimab",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03866993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05321212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + GDC-1971 + Omeprazole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05487235",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Pemetrexed + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02578680",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + EOS884448",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05565378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02409342",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03480230",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01295827",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IMU-201",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04432207",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IBI323",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04916119",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Sirolimus",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04348292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03666143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + CBT-502",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03910127",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ASP1951 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03799003",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RO7121661",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03708328",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Fludarabine + PD-L1 CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03330834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01693562",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anetumab Ravtansine + Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03455556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sasanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04181788",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GRN-1201 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03417882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab or Atezolizumab or Cemiplimab + Sargramostim + UV1 telomerase peptide vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05344209",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Envafolimab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05465733",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous PD-L1\/CD80\/CD86-targeted CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03060343",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04274907",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Nivolumab + Pemetrexed + TG4010",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03353675",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BGB-A445 + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05635708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02008227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Pemetrexed + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05746481",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fecal Microbiota Transplant + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05669846",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LBL-007 + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05635708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Zalifrelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03411473",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BNT116 + Cemiplimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05557591",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tislelizumab + Tucidinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05519865",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pemetrexed + RO7247669",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05775289",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Envafolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05465733",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab + Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04262856",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Radiotherapy + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02888743",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + IO102 + Pembrolizumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03562871",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capmatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04139317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03228667",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Linrodostat + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Endostatin + Envafolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05203276",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Autologous activated NK cells + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03958097",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Durvalumab + Pemetrexed or Vinorelbine + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04765709",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IO102 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03562871",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Mocetinostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02805660",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Vactosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04515979",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bintrafusp alfa + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04396535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04396457",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Eribulin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03222856",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Tumor treating fields",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04392505",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + PULSAR",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04889066",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Hypofractionated radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04351256",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum-based chemotherapy + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT05244837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Nab-paclitaxel + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04015778",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-0482 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04165083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-4830 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04165083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Glumetinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04797702",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + GB1211",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05240131",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IO102 + IO103 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05077709",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Encorafenib + Sasanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04585815",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04925986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Stereotactic Body Radiation Therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03383302",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03523702",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03308942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Denosumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03669523",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GEN1046 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05117242",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GEN1046",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05117242",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Azacitidine oral + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02546986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04164745",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Accelerated Hypofractionated Radiation Therapy + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03801902",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499053",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Standard of care",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04093167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Pembrolizumab + Ramucirumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04340882",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab + Etrumadenant + Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04262856",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"NC318 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04699123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ES101",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04009460",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cibisatamab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03337698",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD2936",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04995523",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04716946",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Itacitinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03425006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"NC318",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04699123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Envafolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05055167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Nab-paclitaxel + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04153734",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04832854",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04167774",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Nab-paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02382406",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03102242",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CIMAvax + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02955290",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02031458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab + Etrumadenant + Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04791839",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenalidomide + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02963610",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04832854",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03563716",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LN-145",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04614103",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05557591",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04262856",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05501665",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Efineptakin alfa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04984811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Docetaxel + Nivolumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05081674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03085069",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Docetaxel + Pembrolizumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05081674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_KRAS_G12C_and_STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JDQ443",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05445843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04563338",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03014648",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02927301",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HLX301",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05102214",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GAd-PEV + MVA-PEV",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04990479",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02453282",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ociperlimab + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04047862",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02766335",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03574402",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03308942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03620669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02879617",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02087423",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Platinum-based chemotherapy + QL1706",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05487391",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03030131",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04108026",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03304093",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03798743",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03170960",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03308942",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03083041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cobimetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03337698",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03571360",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02504372",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03850444",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02864394",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK-7684A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04738487",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zimberelimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04736173",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04203485",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ociperlimab + Platinum-doublet chemotherapy + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05791097",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04252365",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03293680",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02564380",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03083041",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Ramucirumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040361",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04940637",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03800134",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Relatimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750514",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Epacadostat + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03322540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Datopotamab Deruxtecan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05555732",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Datopotamab Deruxtecan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05215340",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Ociperlimab + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04866017",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Pemetrexed + Sugemalimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03789604",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Nab-paclitaxel + Serplulimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04033354",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05211895",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609968",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AK112",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04900363",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03409614",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04475939",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Famitinb",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05042375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03373760",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CBT-502",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04325763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01846416",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CBT-502 + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04325763",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cisplatin + Docetaxel + Paclitaxel + Pemetrexed + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04158440",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pemetrexed + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04507217",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cisplatin + Datopotamab Deruxtecan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05555732",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Fianlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05785767",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab-Vibostolimab + Platinum-doublet chemotherapy + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05298423",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Etoposide + Nivolumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02768558",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02366143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04550260",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bintrafusp alfa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03631706",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Penpulimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03866980",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Penpulimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03866993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03134456",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02352948",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02125461",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02613507",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03856411",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04267848",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02409342",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05047250",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576574",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Monalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05221840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Oleclumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05221840",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Domvanalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04736173",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04736173",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03358875",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03358875",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02395172",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02041533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04203485",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Stereotactic Body Radiation Therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03436056",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab,Pembrolizumab",
        "Description":"Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.",
        "rs value":null,
        "pmid":"PubMed:26086854",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03706690",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02008227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AK112",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05499390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04676412",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02542293",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03829332",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01633970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ociperlimab + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04746924",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Carboplatin + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03134872",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ALK_unspecified_or_EGFR_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Durvalumab + Intensity modulated radiation therapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02087423",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Almonertinib + Envafolimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05534113",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + Pemetrexed + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05527808",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_KRAS_G12C_",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adagrasib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04613596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_KRAS_G12C_",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adagrasib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05609578",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | sarcomatoid carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Ifosfamide + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04224337",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04393883",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03715205",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03003962",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04642469",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02273375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02125461",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03703297",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04624204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04624204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Etoposide + Serplulimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04063163",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT03191786",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02409355",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04547504",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02453282",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tiragolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04294810",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04866017",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Lurbinectedin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04253145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03059667",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05623319",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Etoposide + Lenvatinib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05384015",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BMS-986012 + Carboplatin + Etoposide + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04702880",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03703297",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adebrelimab + Cisplatin + Etoposide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05496166",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Etoposide",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02763579",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dostarlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05565378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03178552",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03131206",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03445000",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":"We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily. 1536 patients with EGFR mutation-negative NSCLC were screened, 34 were RET-positive (2%). 19 were enrolled and 17 patients were eligible for primary analysis.   9 patients (53%) achieved an objective response. At data cutoff, median PFS was 4.7 months.",
        "rs value":null,
        "pmid":"PubMed:27825616",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":"In this phase 1 trial, 57 patients with RET fusion- or mutation positive cancers were treated in 7 dose levels. Among patients with RET-Fusion positive NSCLC, objective response rates were 65% (n = 17\/26). Responses occurred independent of fusion partner (9\/13 KIF5B vs 7\/9 non-KIF5B) and included 3 pts w\/ baseline brain metastases.",
        "rs value":null,
        "pmid":"ASCO:161573",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":"Patients with RET-fusion positive non-small cell lung cancer were enrolled in this phase 1-2 trial of RET inhibitor selpercatinib. Among 105 consecutively enrolled patients who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100).",
        "rs value":null,
        "pmid":"PubMed:32846060",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"KIF5B-RET_fusion_COSF1231",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04222972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"KIF5B-RET_fusion_COSF1231",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"KIF5B-RET_fusion_COSF1231",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01877083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"KIF5B-RET_fusion_COSF1231",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01582191",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03157128",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03037385",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":"RET rearrangements involving RET are found in about 1% of NSCLC and define a unique molecular subset.  This study was a multi-center, open-label, phase II clinical trial to examine the safety and efficacy of Vandetanib (300 mg\/d) in RET positive NSCLC patients (confirmed by FISH), Primary endpoint was the objective response rate. 18 patients were enrolled, the majority were a heavily pretreated population. Among the 17 evaluable patients, three had a partial response (ORR\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd18%) and eight had a stable disease (DCR\ufffd\ufffd\ufffd=\ufffd\ufffd\ufffd65%). Among these patients, the PR or SD was durable for more than 6 months in 8 patients. Vandetanib also showed a PFS of 4.5 months, and an OS of 11.6 months during a median follow-u",
        "rs value":null,
        "pmid":"PubMed:27803005",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01639508",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pemetrexed + Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05364645",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HA121-28",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05117658",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04280081",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":"RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. This was an open-label, two-stage, single-centre, phase 2, single-arm trial in the USA in metastatic\/unresectable lung cancer harbouring RET rearrangement. 26 Patients with lung adenocarcinomas were given 60 mg of cabozantinib orally per day. The primary objective was overall response. Confirmed PR was seen in 7\/25 (ORR 28% [95% CI 12\ufffd\ufffd\ufffd49%]) response-evaluable patients, meeting the primary endpoint. KIF5B-RET was the predominant fusion in 16 (62%) pat",
        "rs value":null,
        "pmid":"PubMed:27825636",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03784378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"DS-5010 ",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03780517",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Agerafenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01877811",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01823068",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pralsetinib + Resection",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04302025",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02540824",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05170204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01813734",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03468985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04131543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:UMIN000010095",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04819100",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04194944",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pralsetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05170204",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selpercatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04268550",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Luminespib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01922583",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_CCDC6::RET",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":"Case report of a 60-year old woman with lung adenocarcinoma. After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedanib-docetaxel trial. Docetaxel was discontinued after 22 cycles because of edema and fatigue. A total of 48 treatment cycles (26 cycles of nintedanib alone) was administered over 33 months before documentation of disease progression in March 2013. Genomic testing revealed a CCDC6-RET fusion but no other actionable mutations (confirmed by FISH).",
        "rs value":null,
        "pmid":"PubMed:26787234",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"CCDC6-RET_fusion_COSF1271",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00876460",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_Fusion",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alectinib",
        "Description":"Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. 4 patients with metastatic RET-rearranged NSCLC were identified. 3 of 4 had received prior RET TKIs, including cabozantinib and experimental RET inhibitors. We observed two (50%) objective radiographic responses after treatment with alectinib (one confirmed and one unconfirmed), with durations of therapy of 6 months and more than 5 months (treatment ongoing). Notably, one of these two patients had his dose of alectinib escalated to 900 mg twice daily and had clinical improvement in central nervous system metastases. In addition, one patient (25%) experienced a best response of stable disease lasting approximately 6 weeks. A fourth patient who was RET TKI-naive had primary progression while receiving alectinib.",
        "rs value":null,
        "pmid":"PubMed:27544060",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_KIF5B::RET",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus,Vandetanib",
        "Description":"Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET\/CT showed systemic response as well.",
        "rs value":null,
        "pmid":"PubMed:25982012",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_KIF5B::RET",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":"A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission in the patient.",
        "rs value":null,
        "pmid":"PubMed:23584301",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V600E",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29596911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V600E",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31542322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RICTOR",
        "Genomic Position":"5:38938021-39074510(-) | 5p13.1",
        "CDS Mutation":null,
        "AA Mutation":"RICTOR_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02593019",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RICTOR",
        "Genomic Position":"5:38938021-39074510(-) | 5p13.1",
        "CDS Mutation":null,
        "AA Mutation":"RICTOR_Amplification",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sapanisertib,Onatasertib",
        "Description":"Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alteration. RICTOR amplification was confirmed via FISH and IHC. On two separate treatments with dual mTOR1\/2 inhibitors patient exhibited stable disease for more than 18 months.",
        "rs value":null,
        "pmid":"PubMed:26370156",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ROS1",
        "Genomic Position":"6:117609463-117747018(-) | 6q22.1",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G2032R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30683630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ensartinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03574402",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576431",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02568267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Entrectinib + Resection",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04302025",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_SQSTM1::NTRK1",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"In 1378 cases of NSCLC screened for NTRK1 rearrangements, 2 were identified (frequency 0.1%). One patient with SQSTM1-NTRK1 was treated with entrectinib in a phase 1 study. The patient had resolution of prior dyspnea and pain within 3 weeks. CT scans showed a partial response and complete resolution of brain metastases. The patient has continued treatment for over 6 months with ongoing PR.",
        "rs value":null,
        "pmid":"PubMed:26565381",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_SQSTM1::NTRK1",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Entrectinib",
        "Description":"Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1\/2\/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.",
        "rs value":null,
        "pmid":"PubMed:28183697",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK1",
        "Genomic Position":"1:156830686-156851434(+) | 1q23.1",
        "CDS Mutation":null,
        "AA Mutation":"NTRK1_G595R_and_G667S",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Larotrectinib",
        "Description":"A 29-year-old male with NTRK-fusion positive NSCLC demonstrated initial response to Larotrectinib but progressed after devloping solvent-front (TRKA G595R) and xDFG (TRKA G667S) mutations.",
        "rs value":null,
        "pmid":"PubMed:30624546",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"WEE1",
        "Genomic Position":"11:9595228-9610754(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"WEE1_RS3910384",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine,Platinum Compound",
        "Description":"The presence of the WEE1 polymorphism rs3910384 correlated with OS and PFS of NSCLC patients treated with platinum-based chemotherapy. Especially the combination of two DNA-damaging agents was associated with efficacy. 663 patients were tested. The authors showed that rs3910384 is closely linked with the putative functional WEE1 promoter at SNPs rs6486433, rs3763869 and rs3763868.",
        "rs value":null,
        "pmid":"PubMed:26057002",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AREG",
        "Genomic Position":"4:75310851-75320726(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"AREG_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":"Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.",
        "rs value":null,
        "pmid":"PubMed:23344087",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"XRCC1",
        "Genomic Position":"19:44047192-44080158(-) | 19q13.31",
        "CDS Mutation":null,
        "AA Mutation":"XRCC1_R194W",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel,Vinorelbine,Gemcitabine",
        "Description":"The XRCC1 R194W variant was shown to be correlated with increased chance of response to platinum-based chemotherapy in Stage IV Non-small Cell Lung Carcinoma (NSCLC). 82 patients with Stage IV NSCLC who had not previously been treated with chemotherapy were used in this study.",
        "rs value":null,
        "pmid":"PubMed:19157633",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12\/G13",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib,Erlotinib",
        "Description":"In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9\/38 refractory vs 0\/21 sensitive patients; P=0.0201).",
        "rs value":null,
        "pmid":"PubMed:15696205",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12A",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib,Gefitinib",
        "Description":"KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) were significantly shorter in mutated patients.",
        "rs value":null,
        "pmid":"PubMed:19794967",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"Lung Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).",
        "rs value":null,
        "pmid":"PubMed:17409929",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12D",
        "Disease":"Lung Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).",
        "rs value":null,
        "pmid":"PubMed:17409929",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":"In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib and placebo, patients whose tumors harbored KRAS mutations (n=8) had a lower 12-week progression-free survival rate (0% vs. 37%, P=0.0390) compared to wildtype KRAS patients (n=35). Authors concluded that KRAS mutation was associated with poor response to erlotinib monotherapy.",
        "rs value":null,
        "pmid":"PubMed:22025157",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12A",
        "Disease":"Lung Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).",
        "rs value":null,
        "pmid":"PubMed:17409929",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib,Erlotinib",
        "Description":"In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. KRAS mutations (n=11) were associated with lack of objective response to drug treatment (0.0% vs. 35.7%, p=0.03), no significant difference in overall survival (19.3 vs. 28.6 months, p=0.47), and shorter median time to progression (2.7 vs. 5.6 months, p=0.003) when compared to wild-type KRAS. Through multivariate analyses, it was shown that KRAS mutations were significant predictors of shorter time to progression (HR: 2.43, 95% CI: 1.23-4.79, p=0.01).",
        "rs value":null,
        "pmid":"PubMed:21258250",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib,Teprotumumab",
        "Description":"In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib daily and teprotumumab (R1507) weekly or every three weeks, patients whose tumors harbored KRAS mutations had similar progression free survival rates compared to patients with wt KRAS. Among patients given R1507 weekly, those whose tumors had KRAS mutations (n=16) had a 12-week progression free survival (PFS) rate of 25% compared to 30% for KRAS wt patients (n=27; p = 0.7436). For patients given R1507 (teprotumumab) every three weeks, 12-week PFS rate for patients with KRAS mt tumors (n=12) was 50% compared to 27% for patients with KRAS wt tumors (n=34; p=0.1350). Authors concluded that KRAS mutation was predictive of a favorable response to erlotinib + R1507 combination therapy.",
        "rs value":null,
        "pmid":"PubMed:22025157",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12S",
        "Disease":"Lung Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).",
        "rs value":null,
        "pmid":"PubMed:17409929",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":"In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, KRAS mutation was assessed. In the KRAS wildtype group, erlotinib showed a significant benefit for progression free survival (PFS) over placebo (HR, 0.70; 95% CI, 0.57 to 0.87, P<0.001). No statistically significant improvement in PFS was seen with erlotinib in the KRAS mutant group over placebo. Significant difference in PFS between erlotinib treated KRAS WT and MUT patients was not seen.  Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001).",
        "rs value":null,
        "pmid":"PubMed:21969500",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib + Selumetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02450656",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Tivantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01395758",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Tivantinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00777309",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Methotrexate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03520842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Foretinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01068587",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Selumetinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01229150",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01859026",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab biosimilar Mvasi + Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05180422",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03299088",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib,Pemetrexed,Docetaxel",
        "Description":"This phase I\/Ib two-part study evaluated trametinib in combination with anticancer agents docetaxel or pemetrexed in NSCLC with and without KRAS mutations. Confirmed partial response (PR) was observed in 21% (10\/47) patients receiving trametinib\/docetaxel. The ORR was 18% (4 PR in 22 patients) in KRAS wild-type versus 24% (six PR in 25 patients) in KRAS-mutant NSCLC. Of the 42 patients treated with trametinib\/pemetrexed, 14% (6\/42) had a PR; the ORR was 17% (4\/23) in KRAS-mutated NSCLC versus 11% (2\/19) in KRAS wild-type NSCLC.",
        "rs value":null,
        "pmid":"PubMed:27876675",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_CD274_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03823625",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":"In a phase 1 clinical trial for the use of trametinib for various advanced solid tumors, 22 out of 30 NSCLC patients harbored KRAS mutations. Of those 22 patients with mutant KRAS, 8 saw reductions in tumor size ranging from 6-52% including 2 partial responses.",
        "rs value":null,
        "pmid":"PubMed:22805291",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04967079",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01362296",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12_or_KRAS_G13",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipilimumab + KRAS peptide vaccine + Nivolumab + poly ICLC",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05254184",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Momelotinib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02258607",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Naporafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02974725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ponatinib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03704688",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avutometinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03681483",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RMC-4630",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03634982",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adagrasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05673187",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JDQ443",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05445843",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BBP-398 + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05375084",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RMC-4630 + Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05054725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12V",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel,Selumetinib",
        "Description":"83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations receiving combination selumetinib and docetaxel had a trend towards longer OS, PFS and ORR compared to other KRAS mutations. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo.",
        "rs value":null,
        "pmid":"PubMed:26125448",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab,Atezolizumab",
        "Description":"A meta-analysis of randomized trials to investigate if KRAS mutation status affects survival benefits of immune checkpoint inhibition (ICI) in patients with advanced NSCLC. Of 3 eligible studies using either nivolumab or atezolizumab, 138 patients with KRAS mutant NSCLC and 371 with KRAS wild-type were included. ICI improved overall survival over that with docetaxel in KRAS mutant, previously-treated advanced NSCLC (hazard ratio=0.64 [95% confidence interval, 0.43-0.96], P = 0.03) but not in those with KRAS wild-type tumor (HR = 0.88 [95% CI, 0.68-1.13], P = 0.30). These results suggest that KRAS mutation status may be a potential biomarker for survival benefits to ICIs.",
        "rs value":null,
        "pmid":"PubMed:28525386",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selumetinib,Docetaxel",
        "Description":"83 patients from a phase II trial (docetaxel + placebo or MEK1\/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations receiving selumetinib and docetaxel combined treatment had a trend towards longer OS, PFS and ORR compared to other KRAS mutations, but the differences did not reach statistical significance. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo.",
        "rs value":null,
        "pmid":"PubMed:26125448",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selumetinib,Docetaxel",
        "Description":"87 patients with KRAS mutant stage IIB-IV NSCLC after first line therapy were randomly assigned (1:1) to oral selumetunib and docetaxel or docetaxel and Placebo. Median OS was 9\ufffd\ufffd4 months (6\ufffd\ufffd8-13\ufffd\ufffd6) in selumetinib group and 5\ufffd\ufffd2 months (95% CI 3\ufffd\ufffd8-non-calculable) in placebo group (hazard ratio [HR] for death 0\ufffd\ufffd80, 80% CI 0\ufffd\ufffd56-1\ufffd\ufffd14; one-sided p=0\ufffd\ufffd21). Median PFS was 5\ufffd\ufffd3 months (4\ufffd\ufffd6-6\ufffd\ufffd4) in selumetinib group and 2\ufffd\ufffd1 months (95% CI 1\ufffd\ufffd4-3\ufffd\ufffd7) in placebo group (HR for progression 0\ufffd\ufffd58, 80% CI 0\ufffd\ufffd42-0\ufffd\ufffd79; one-sided p=0\ufffd\ufffd014). An objective response was observed in 16 (37%)",
        "rs value":null,
        "pmid":"PubMed:23200175",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib",
        "Description":"The phase II cohort of the CodeBreaK 100 study (NCT03600883) investigated the activity of the KRAS G12C inhibitor sotorasib in previously treated patients with KRAS G12C-mutated non-small cell lung cancer. A total of 124 patients had measurable disease and were evaluated for response by independent central review. Complete response was seen in four patients and partial response in 42 patients, for an objective response rate of 37.1% (95% CI, 28.6 to 46.2). The median progression-free survival and overall survival were 6.8 (95% CI, 5.1 to 8.2) months and 12.5 months (95% CI, 10.0 to could not be evaluated), respectively.",
        "rs value":null,
        "pmid":"PubMed:34096690",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":"In this multicenter phase I study of abemaciclib, a total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. The disease control rate for the KRAS-mutant population was 55% (16\/29) compared to 39% (13\/33)  in KRAS wildtype cohort. Stable disease lasting \ufffd\ufffd\ufffd24 weeks was achieved for 31% (9\/29) with KRAS-mutant disease vs 12% (4\/33) with KRAS wild-type disease. Median PFS was 2.8 months and 1.9 months for the KRAS-mutant and KRAS wild-type populations, respect",
        "rs value":null,
        "pmid":"PubMed:27217383",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JDQ443",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05132075",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT04303780",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adagrasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04685135",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Midazolam + Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03600883",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04625647",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib + Zotatifin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04092673",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + GFH925",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05756153",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Docetaxel,Selumetinib",
        "Description":"A phase 3 study of selumetinib and docetaxel in KRAS mutant, previously treated NSCLC. 866 were enrolled and 510 randomized. Median progression-free survival was 3.9 months with selumetinib\ufffd\ufffd\ufffd+\ufffd\ufffd\ufffddocetaxel and 2.8 months with placebo\ufffd\ufffd\ufffd+\ufffd\ufffd\ufffddocetaxel. Median overall survival was 8.7 months with selumetinib\ufffd\ufffd\ufffd+\ufffd\ufffd\ufffddocetaxel and 7.9 months with placebo\ufffd\ufffd\ufffd+\ufffd\ufffd\ufffddocetaxel. Objective response rate was 20.1% with selumetinib\ufffd\ufffd",
        "rs value":null,
        "pmid":"PubMed:28492898",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C_and_STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"JAB-21822",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05276726",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05631249",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12_or_KRAS_G13_or_KRAS_Q61",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT00411671",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_or_STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GFH925 + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05504278",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adagrasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05472623",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05451056",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05400577",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05398094",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"D-1553 + Physician's choice",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05492045",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05311709",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib + VIC-1911",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05374538",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adagrasib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03785249",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04380753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"GFH925 + Pemetrexed + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05504278",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin or Cisplatin + GFH925 + Pemetrexed + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05504278",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adagrasib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04613596",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03600883",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + GFH925",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05504278",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12_or_KRAS_G13",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cetuximab + Selumetinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01217450",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C_and_STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04933695",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_or_STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adagrasib + Avutometinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05375994",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_CD274_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02779751",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HS-10370",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05367778",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_CD274_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02779751",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dasatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00787267",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TVB2640",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03808558",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Defactinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04620330",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RO4987655",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02451865",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ERAS-007",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03415126",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"LTT462 + Naporafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02974725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Naporafenib + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02974725",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03574402",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cobimetinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01988896",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_CD274_unspecified",
        "Disease":"pleura | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anetumab Ravtansine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03126630",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_CD274_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Finotonlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04171284",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_CD274_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03823625",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"IMM-1-104",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05585320",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BGB-3245 + Mirdametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05580770",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Zotatifin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04092673",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avutometinib + Defactinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04620330",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Rigosertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04263090",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Salirasib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00531401",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Selinexor",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03095612",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pelareorep + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01708993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Pelareorep",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01708993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sotorasib + Tarloxotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05313009",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemetrexed + Platinum-based chemotherapy + Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05118854",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avutometinib + Sotorasib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05074810",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HL-085 + Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03990077",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lifirafenib + Mirdametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03905148",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Hydroxychloroquine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04735068",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03777124",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_CD274_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03666143",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12C",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"VIC-1911",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05374538",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Durvalumab + Pemetrexed",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04470674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04470674",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Pelareorep",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT00998192",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00863746",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT02152631",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avutometinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04620330",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Pelareorep",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00861627",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Spartalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03693326",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_A146V",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":"Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led to administration of CDK4 inhibitor LY2835219. Specifically, the PHIAL algorithm nominated this variant as actionable on the basis of a predicted synthetic lethal relationship between activated KRAS and CDK4. The patient achieved stable disease and was on treatment for 16 weeks which was the patients best and only clinical response to any cancer-directed therapy.",
        "rs value":null,
        "pmid":"PubMed:24836576",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12V",
        "Disease":"Lung Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).",
        "rs value":null,
        "pmid":"PubMed:17409929",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ARAF",
        "Genomic Position":"X:47420516-47431299(+) | Xp11.3",
        "CDS Mutation":null,
        "AA Mutation":"ARAF_S214C",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sorafenib",
        "Description":"In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.",
        "rs value":null,
        "pmid":"PubMed:24569458",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NRG1",
        "Genomic Position":"8:32405728-32622548(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"NRG1_Expression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab",
        "Description":"In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictive biomarker but prospectively assessed in 102 patients before unblinding. NRG1-high groups demonstrated clinical benefit from additional patritumab with hazard ratios of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively.",
        "rs value":null,
        "pmid":"PubMed:26137564",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NRG1",
        "Genomic Position":"8:32405728-32622548(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"NRG1_SDC4::NRG1",
        "Disease":"Lung Adenocarcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Afatinib",
        "Description":"In patient with lung adenocarcinoma an SDC4-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the detected gene fusion, prioritizing therapeutic strategies targeting the HER-family of growth factor receptors. This patient was treated with the pan HER-family kinase inhibitor afatinib and displayed a significant and durable response to treatment.",
        "rs value":null,
        "pmid":"PubMed:28950338",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RRM1",
        "Genomic Position":"11:4116039-4160106(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"RRM1_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Gemcitabine",
        "Description":"In the personalized therapy group of this study, patients received chemotherapy based on RRM-1 IHC expression levels, whereas the standard therapy group received non-customized chemotherapy. There were statistically significant improvements between the personalized therapy group versus the standard therapy group in disease control rate (82.9% vs 55.3%, P=0.004), and progression-free survival (median: 5.5 months vs 3.0 months, P=0.005). Besides, the overall survival had a tendency to become more prolonged (median: 16.0 months vs 12.4 months, P=0.286).",
        "rs value":null,
        "pmid":"PubMed:24595080",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RRM1",
        "Genomic Position":"11:4116039-4160106(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"RRM1_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine",
        "Description":"In this study, 229 tumors were analyzed for RRM1 expression. This resulted in 146 that were negative for RRM1 expression and 83 that were positive. These tumors were studied for a relationship between RRM1 expression and chemotherapy regimens, gemcitabine, docetaxel and carboplatin, and vinorelbine and carboplatin. In the patients receiving gemcitabine treatment, the progression-free survival of RRM1-negative patients was significantly higher than that of RRM1-positive patients (8.8 months vs. 7.6 months, P = 0.01). The patients that were positive for RRM1 expression, had a better response to docetaxel or vinorelbine treatment than gemcitabine (P=0.047 and P=0.047). However, there were no differences of response to docetaxel and vinorelbine in regards to RRM1 expression.",
        "rs value":null,
        "pmid":"PubMed:24647522",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RRM1",
        "Genomic Position":"11:4116039-4160106(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"RRM1_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vinorelbine,Paclitaxel,Gemcitabine",
        "Description":"The study began with a total of 443 patients that were randomly assigned to either regimen A (Paclitaxel and cisplatin with gemcitabine) or regimen B ( cisplatin and vinorelbine). Of those patients, 261 had tissue available for RRM1 evaluation. In regimen B, survival increased significantly in patients with low RRM1 expression as compared to those with a high expression (P=0.046). However, in regimen A, the increase in survival for patients with low RRM1 expression as opposed to those with a high RRM1 expression was not as significant (P=0.366).",
        "rs value":null,
        "pmid":"PubMed:23038758",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RRM1",
        "Genomic Position":"11:4116039-4160106(+) | 11p15.4",
        "CDS Mutation":null,
        "AA Mutation":"RRM1_Underexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gemcitabine,Carboplatin",
        "Description":"As part of a randomized phase III trial (USO-03012) in advanced NSCLC of gemcitabine vs. combination gemcitabine and carboplatin, protein expression levels for RRM1 (n=69) and ERCC1 (n=65) were evaluated using fluorescence-based IHC. RRM1 levels were significantly inversely correlated with response (r = \ufffd\ufffd\ufffd0.41; P = .001, n=58), as were ERCC1 levels (r = \ufffd\ufffd\ufffd0.39; P = .003, n=55). RRM1 and ERCC1 levels were correlated with each other (r = 0.36; P = .003, n=65). There was no significant interaction with treatment arm (P = .64 for RRM1; P = .79 for ERCC1). The authors conclude that RRM1 and ERCC1 expression levels are predictive of response to gemcitabine, and gemcitabine and ",
        "rs value":null,
        "pmid":"PubMed:19884554",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"HAVCR2",
        "Genomic Position":"5:156512843-156536725(-) | 5q33.3",
        "CDS Mutation":null,
        "AA Mutation":"HAVCR2_Overexpression",
        "Disease":"Lung Non-small Cell Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"PD1 Inhibitor",
        "Description":"In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody. Two patients who developed adaptive resistance to anti-PD-1 treatment also showed TIM-3 upregulation in blocking antibody-bound T cells at treatment failure.",
        "rs value":null,
        "pmid":"PubMed:26883990",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29596911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28961830",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28271038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29506987",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32122695",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28274743",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.L982",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31157314",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Osimertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31561203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27694386",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1249Y",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y1248H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27987579",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3742T>C",
        "AA Mutation":"p.Y1248H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y1248H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28522754",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27987579",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27987579",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28522754",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.G1181R",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28522754",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3743A>G",
        "AA Mutation":"p.Y1248C",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27666659",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3736G>A",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3736G>A",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27343442",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32122695",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y1248S",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28522754",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y1248H",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:29128427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31561203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3736G>A",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Capmatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3742T>C",
        "AA Mutation":"p.Y1248H",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Capmatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28396313",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30711944",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3737A>T",
        "AA Mutation":"p.D1246V",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Savolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27694386",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Gemcitabine + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01282333",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03845296",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03009682",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_ATM_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CDK12_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_RAD51_unspecified_or_RAD54L_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04276376",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_CD274_unspecified_or_ERCC1_unspecified_or_KEAP1_unspecified_or_SLFN11_unspecified_or_STK11_unspecified_or_TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05568212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_CD274_unspecified_or_ERCC1_unspecified_or_KEAP1_unspecified_or_SLFN11_unspecified_or_STK11_unspecified_or_TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05568212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_CD274_unspecified_or_ERCC1_unspecified_or_KEAP1_unspecified_or_SLFN11_unspecified_or_STK11_unspecified_or_TP53_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib + Platinum-doublet chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05568212",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Docetaxel + Erlotinib + Pegfilgrastim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01557959",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02154490",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CCND2_unspecified_or_CCND3_unspecified_or_CDK4_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02785939",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRA",
        "Genomic Position":"4:55095264-55164414(+) | 4q12",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"XZP-3621",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05204628",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified_or_CBL_unspecified_or_KDR_unspecified_or_KIT_unspecified_or_MET_unspecified_or_NTRK1_unspecified_or_NTRK2_unspecified_or_NTRK3_unspecified_or_PDGFRA_unspecified_or_RET_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AXL",
        "Genomic Position":"19:41725108-41767671(+) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AXL_unspecified_or_MET_unspecified_or_NTRK1_fusions_or_NTRK2_fusions_or_NTRK3_fusions",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01639508",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TERT",
        "Genomic Position":"5:1253282-1295162(-) | 5p15.33",
        "CDS Mutation":null,
        "AA Mutation":"TERT_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vx-001",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01935154",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2L1",
        "Genomic Position":"20:30252255-30310701(-) | 20q11.21",
        "CDS Mutation":null,
        "AA Mutation":"BCL2L1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00378404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_(VEGFR1_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_(VEGFR1_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT1",
        "Genomic Position":"13:28874489-29069232(-) | 13q12.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT1_unspecified_(VEGFR1_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TSC1",
        "Genomic Position":"9:135766735-135820008(-) | 9q34",
        "CDS Mutation":null,
        "AA Mutation":"TSC1_unspecified_or_TSC2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"HRAS",
        "Genomic Position":"11:532243-535550(-) | 11p15.5",
        "CDS Mutation":null,
        "AA Mutation":"HRAS_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tipifarnib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03496766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02117167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"POU2F3",
        "Genomic Position":"11:120107349-120190653(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"POU2F3_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"lung | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02264678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1895344 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04095273",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03009682",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Berzosertib + Carboplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04216316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD51_unspecified_or_RAD51B_unspecified_or_RAD54L_unspecified_or_RPA1_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03377556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SI-B001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05044897",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RECQL5",
        "Genomic Position":"17:73622934-73663269(-) | 17q25",
        "CDS Mutation":null,
        "AA Mutation":"RECQL5_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51",
        "Genomic Position":"15:40987372-41023791(+) | 15q15.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD51_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD52",
        "Genomic Position":"12:1021243-1058888(-) | 12p13.33",
        "CDS Mutation":null,
        "AA Mutation":"RAD52_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_S249C",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02965378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02154490",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"(CDKN2A_unspecified_and_TP53_unspecified)_or_MYC_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02688907",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"(CDKN2A_unspecified_and_TP53_unspecified)_or_MYC_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02593019",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02693535",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01291017",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":null,
        "AA Mutation":"MAP2K1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selumetinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02117167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGF1",
        "Genomic Position":"5:141971743-142000907(-) | 5q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FGF1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGF1",
        "Genomic Position":"5:141971743-142000907(-) | 5q31.3",
        "CDS Mutation":null,
        "AA Mutation":"FGF1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD54L",
        "Genomic Position":"1:46713404-46744144(+) | 1p34.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD54L_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51B",
        "Genomic Position":"14:68286525-69062713(+) | 14q24.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD51B_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":null,
        "AA Mutation":"ESR1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00592007",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":null,
        "AA Mutation":"FGFR2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bemarituzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05267470",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":null,
        "AA Mutation":"FGFR2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bemarituzumab + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05267470",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":null,
        "AA Mutation":"FGFR2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":null,
        "AA Mutation":"FGFR2_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02154490",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":null,
        "AA Mutation":"FGFR2_unspecified",
        "Disease":"lung | carcinoma | squamous cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02965378",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":null,
        "AA Mutation":"FGFR2_unspecified_or_FGFR3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Entrectinib + Resection",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04302025",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTOR",
        "Genomic Position":"1:11166592-11322564(-) | 1p36.22",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTOR",
        "Genomic Position":"1:11166592-11322564(-) | 1p36.22",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":"c.1",
        "AA Mutation":"p.0",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF1",
        "Genomic Position":"17:29421945-29704695(+) | 17q11.2",
        "CDS Mutation":"c.7175G>A",
        "AA Mutation":"p.G2392E",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tyrosine kinase inhibitor - NS",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28818608",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NTRK2",
        "Genomic Position":"9:87283466-87638505(+) | 9q21.33",
        "CDS Mutation":null,
        "AA Mutation":"NTRK2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Entrectinib + Resection",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04302025",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00378404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Etoposide + Navitoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00878449",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Interferon alpha-2B + Isotretinoin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00062010",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Oblimersen sodium + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00005032",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified_and_EGFR_unspecified",
        "Disease":"lung | carcinoma | adenocarcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Icotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02044328",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"WT2725",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01621542",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Interleukin-2 + WT1-TCRc4 gene-transduced autologous CD8-positive Tcm\/Tn lymphocytes",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02408016",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Pembrolizumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03761914",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"pleura | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Nivolumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04040231",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"pleura | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Montanide + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01265433",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"pleura | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Pemetrexed + WT1 mRNA transfected autologous DC vaccine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02649829",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"pleura | mesothelioma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Montanide + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01890980",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CBL",
        "Genomic Position":"11:119076752-119178859(+) | 11q23.3",
        "CDS Mutation":null,
        "AA Mutation":"CBL_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sitravatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02219711",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BAX",
        "Genomic Position":"19:49458186-49465055(+) | 19q13.33",
        "CDS Mutation":null,
        "AA Mutation":"BAX_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00378404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SY-3505",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05257512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02117167",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01306045",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01306045",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PTEN_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN1A",
        "Genomic Position":"6:36646487-36655108(+) | 6p21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDKN1A_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00378404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NBN",
        "Genomic Position":"8:90945564-90996944(-) | 8q21.3",
        "CDS Mutation":null,
        "AA Mutation":"NBN_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RECQL",
        "Genomic Position":"12:21621845-21654527(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"RECQL_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD50",
        "Genomic Position":"5:131892630-131979752(+) | 5q31.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD50_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MRE11",
        "Genomic Position":"11:94152895-94227074(-) | 11q21",
        "CDS Mutation":null,
        "AA Mutation":"MRE11_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MRE11",
        "Genomic Position":"11:94152895-94227074(-) | 11q21",
        "CDS Mutation":null,
        "AA Mutation":"MRE11_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03009682",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":"c.2447A>G",
        "AA Mutation":"p.D816G",
        "Disease":"carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27068398",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51C",
        "Genomic Position":"17:56769934-56811703(+) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RAD51C_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":null,
        "AA Mutation":"NRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Binimetinib + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02451865",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":null,
        "AA Mutation":"NRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Selumetinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02664935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NRAS",
        "Genomic Position":"1:115247090-115259515(-) | 1p13.2",
        "CDS Mutation":null,
        "AA Mutation":"NRAS_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Spartalizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03693326",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SMO",
        "Genomic Position":"7:128828713-128853386(+) | 7q32.1",
        "CDS Mutation":null,
        "AA Mutation":"SMO_P641A",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vismodegib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WRN",
        "Genomic Position":"8:30891317-31031285(+) | 8p12",
        "CDS Mutation":null,
        "AA Mutation":"WRN_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"JAK2",
        "Genomic Position":"9:4985245-5128183(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"JAK2_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Pemetrexed + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02119650",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RPA1",
        "Genomic Position":"17:1733278-1802848(+) | 17p13.3",
        "CDS Mutation":null,
        "AA Mutation":"RPA1_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT4",
        "Genomic Position":"5:180028506-180076624(-) | 5q35.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT4_unspecified_(VEGFR3_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT4",
        "Genomic Position":"5:180028506-180076624(-) | 5q35.3",
        "CDS Mutation":null,
        "AA Mutation":"FLT4_unspecified_(VEGFR3_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BLM",
        "Genomic Position":"15:91260558-91358692(+) | 15q26.1",
        "CDS Mutation":null,
        "AA Mutation":"BLM_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CSF1R",
        "Genomic Position":"5:149432854-149492935(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"CSF1R_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CSF1R",
        "Genomic Position":"5:149432854-149492935(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"CSF1R_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":null,
        "AA Mutation":"FLT3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FLT3",
        "Genomic Position":"13:28577411-28674729(-) | 13q12.2",
        "CDS Mutation":null,
        "AA Mutation":"FLT3_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RECQL4",
        "Genomic Position":"8:145736667-145743210(-) | 8q24.3",
        "CDS Mutation":null,
        "AA Mutation":"RECQL4_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KDR",
        "Genomic Position":"4:55944644-55991756(-) | 4q12",
        "CDS Mutation":null,
        "AA Mutation":"KDR_unspecified_(VEGFR2_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erlotinib + Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00265317",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KDR",
        "Genomic Position":"4:55944644-55991756(-) | 4q12",
        "CDS Mutation":null,
        "AA Mutation":"KDR_unspecified_(VEGFR2_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00372775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KDR",
        "Genomic Position":"4:55944644-55991756(-) | 4q12",
        "CDS Mutation":null,
        "AA Mutation":"KDR_unspecified_(VEGFR2_unspecified)",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nintedanib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"SLFN11",
        "Genomic Position":"17:33677324-33700639(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"SLFN11_unspecified",
        "Disease":"lung | carcinoma | small cell carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04939662",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KEAP1",
        "Genomic Position":"19:10596796-10614417(-) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"KEAP1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed + Telaglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04265534",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KEAP1",
        "Genomic Position":"19:10596796-10614417(-) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"KEAP1_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sirpiglenastat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04471415",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KEAP1",
        "Genomic Position":"19:10596796-10614417(-) | 19p13.2",
        "CDS Mutation":null,
        "AA Mutation":"KEAP1_unspecified_or_STK11_unspecified",
        "Disease":"lung | carcinoma | non small cell carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF2",
        "Genomic Position":"22:29999547-30094587(+) | 22q12.2",
        "CDS Mutation":"c.592C>T",
        "AA Mutation":"p.R198*",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24813888",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF2",
        "Genomic Position":"22:29999547-30094587(+) | 22q12.2",
        "CDS Mutation":"c.811-2A>T",
        "AA Mutation":"p.?",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Afatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24813888",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CB",
        "Genomic Position":"3:138372860-138553594(-) | 3q22.3",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D1067V",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Erlotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25982275",
        "source_db":"COSMIC"
    }
]